ACADIA Pharmaceuticals Inc at TD Cowen Novel Mechanisms in Neuropsychiatry Summit Transcript
Good evening, everyone. Thank you for joining us for the last session of TD Cowen's Third Annual Innovations in Neuropsychiatry Summit. Our last fireside chat and session for today is ACADIA Pharmaceuticals. With us today from ACADIA, we have Steve Davis, President and CEO, as well as Doug Williamson, EVP, Head of Research and Development. Thank you, guys, for joining us.
Steve, I'm going to turn it over to you for some brief opening remarks just on the state of the union of ACADIA before we jump into -204 first, I've decided.
I'll be brief so that we can get back to the heart of the activity here in Q&A. At ACADIA, we have two commercial franchises, one in Parkinson's disease psychosis where our first approved drug, NUPLAZID, is generating well over $0.5 billion a year in revenues. Our focus on that franchise is cash flow and profitability. That franchise on a stand-alone, fully burdened basis has been profitable and cash flow positive since 2019. It's now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
